← Back to Search

Sulfur Donor

UW (perfusion solution) + sodium thiosulfate (STS) for Kidney Failure

Phase 1
Waitlist Available
Led By Alp Sener, Dr.
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will determine if thiosulfate improves kidney function in recipients of deceased donor kidneys.

Eligible Conditions
  • Kidney Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Patient urine output
Patient urine output
Serum Creatinine
+2 more
Secondary outcome measures
Biopsy proven Acute tubular necrosis (ATN)
Urinary injury biomarkers (KIM-1/NGAL).
Urine protein/creatinine ratio

Trial Design

2Treatment groups
Active Control
Group I: UW (perfusion solution) + sodium thiosulfate (STS)Active Control1 Intervention
We will flush the deceased donor kidney with UW (perfusion solution) + sodium thiosulfate (STS)
Group II: UW (perfusion solution)Active Control1 Intervention
Kidney will be flushed with UW (perfusion solution) which is the normal standard of care.

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
654 Previous Clinical Trials
413,197 Total Patients Enrolled
2 Trials studying Kidney Failure
41 Patients Enrolled for Kidney Failure
Alp Sener, Dr.Principal InvestigatorLHSC

Media Library

Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25% (Sulfur Donor) Clinical Trial Eligibility Overview. Trial Name: NCT04292184 — Phase 1
Kidney Failure Research Study Groups: UW (perfusion solution) + sodium thiosulfate (STS), UW (perfusion solution)
Kidney Failure Clinical Trial 2023: Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25% Highlights & Side Effects. Trial Name: NCT04292184 — Phase 1
Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25% (Sulfur Donor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04292184 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many volunteers have been recruited to participate in this experiment?

"Unfortunately, recruitment for this trial has been completed. The study was initiated on March 21st 2021 and the latest update to their database occurred October 6th 2021. If you are looking for alternatives, there are presently 586 trials recruiting participants with kidney diseases as well as 17 studies that require UW (perfusion solution) + sodium thiosulfate (STS)."

Answered by AI

Could you elucidate any other scientific investigations conducted concerning the combination of UW and STS?

"Currently, there are 17 clinical trials in various stages of research for UW (perfusion solution) + sodium thiosulfate (STS). Three have reached Phase 3. Lismore, New South Wales is the epicentre of this research with many other locations also running related studies."

Answered by AI

Are enrollees being accepted for this medical experiment presently?

"The information stored on clinicaltrials.gov suggests that this medical trial is not actively recruiting patients, despite having originally been posted in March 2021 and last updated in October of the same year. Nevertheless, there are 603 other trials searching for participants as of now."

Answered by AI

Has the FDA given authorization to administer UW in conjunction with sodium thiosulfate?

"With limited data on UW (perfusion solution) + sodium thiosulfate (STS)'s safety and efficacy, this combination only scored a 1 in terms of security."

Answered by AI
~5 spots leftby Mar 2025